Huons said Tuesday that it would market in Korea the generic peptide treatment of Ambio, a U.S. based pharmaceutical company. Huons CEO Um Key-an (right) and Ambio CEO Chris Bai hold up their agreement at Huons headquarters in Seongnam, Gyeonggi Province, on Monday. Under the accord, Huons plans to use its domestic sales and marketing know-how to expand the unfamiliar peptide drug market in Korea. Ambio’s peptide pipeline covers illnesses such as diabetes, obesity, central nervous system and osteoporosis. Huons expects that the parathyroid hormone (PTH) drug being developed by Ambio will become a new treatment option for about 900,000 osteoporosis patients in Korea. Unlike conventional bone resorption inhibitors, PTH drugs are bone growth promoters as they stimulate the function of osteoclasts to produce new bones. The domestic market is worth 20 billion won ($17.4 million) and has recorded the high annual growth rate of 30 percent over the past five years. “To sustain the growth of Huons, we have decided to advance into the peptide drug market,” Huons CEO Um Key-an said. “With Ambio's superior R&D and production technology, we will quickly lead the peptide drug market into the domestic market.” Ambio CEO Chris Bai also said, “We are very pleased to be able to enter the Korean pharmaceutical market with Huons. As peptide drugs are attracting attention in the global healthcare market, we will build a win-win business model by promoting joint development between the two companies.” tweet Lee Han-soo corea022@docdocdoc.co.kr See Other Articles Copyright © KBR Unauthorized reproduction, redistribution prohibited News That You Haven't Seen ‘Aggressive interferon treatment needed to reach MRD in myeloproliferative neoplasms’ Polycythemia vera moves a step closer to potential cure Generative AI, top investment priority for 62% of healthcare CEOs: KHIDI report Handok and Swedish Orphan Biovitrum launch joint venture in Korea [Column] Why eating microplastics is harmful Samsung Bioepis secures 1st approval in Korea for Stelara biosimilar ‘Goal of treating hemophilia is to normalize life like a non-patient’ ‘Aggressive interferon treatment needed to reach MRD in myeloproliferative neoplasms’ Comments Log In 작성자 비밀번호 댓글 내용입력 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More Delete comments Deleted comments cannot be recovered. Do you still want to delete it? Password 닫기 Modify the comments You can modify comments only within 1 minute after writing. Text / 400 Password 닫기 My comment collection 닫기 Important News New research offers hope in multiple myeloma treatment through enhanced NK cell function Fexuclue sales soar 57% in Q1, boosting Daewoong's GERD market growth RIGHT Foundation opens grants for global health equity in infectious disease VUNO introduces cardiac arrest risk monitoring device at critical care society’s meet SNUH to suspend all treatments next Tuesday as senior doctors leave hospital Viatris celebrates Lipitor's vital role in dyslipidemia control, CVD prevention in Korea
Huons said Tuesday that it would market in Korea the generic peptide treatment of Ambio, a U.S. based pharmaceutical company. Huons CEO Um Key-an (right) and Ambio CEO Chris Bai hold up their agreement at Huons headquarters in Seongnam, Gyeonggi Province, on Monday. Under the accord, Huons plans to use its domestic sales and marketing know-how to expand the unfamiliar peptide drug market in Korea. Ambio’s peptide pipeline covers illnesses such as diabetes, obesity, central nervous system and osteoporosis. Huons expects that the parathyroid hormone (PTH) drug being developed by Ambio will become a new treatment option for about 900,000 osteoporosis patients in Korea. Unlike conventional bone resorption inhibitors, PTH drugs are bone growth promoters as they stimulate the function of osteoclasts to produce new bones. The domestic market is worth 20 billion won ($17.4 million) and has recorded the high annual growth rate of 30 percent over the past five years. “To sustain the growth of Huons, we have decided to advance into the peptide drug market,” Huons CEO Um Key-an said. “With Ambio's superior R&D and production technology, we will quickly lead the peptide drug market into the domestic market.” Ambio CEO Chris Bai also said, “We are very pleased to be able to enter the Korean pharmaceutical market with Huons. As peptide drugs are attracting attention in the global healthcare market, we will build a win-win business model by promoting joint development between the two companies.”
News That You Haven't Seen ‘Aggressive interferon treatment needed to reach MRD in myeloproliferative neoplasms’ Polycythemia vera moves a step closer to potential cure Generative AI, top investment priority for 62% of healthcare CEOs: KHIDI report Handok and Swedish Orphan Biovitrum launch joint venture in Korea [Column] Why eating microplastics is harmful Samsung Bioepis secures 1st approval in Korea for Stelara biosimilar ‘Goal of treating hemophilia is to normalize life like a non-patient’
Comments Log In 작성자 비밀번호 댓글 내용입력 댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More
댓글 정렬 Newest Recommended Top Comments BEST Comments BEST Comments It is automatically exposed by adding up the number of replies and recommendations. 닫기 More
Important News New research offers hope in multiple myeloma treatment through enhanced NK cell function Fexuclue sales soar 57% in Q1, boosting Daewoong's GERD market growth RIGHT Foundation opens grants for global health equity in infectious disease VUNO introduces cardiac arrest risk monitoring device at critical care society’s meet SNUH to suspend all treatments next Tuesday as senior doctors leave hospital Viatris celebrates Lipitor's vital role in dyslipidemia control, CVD prevention in Korea